Obamacare survivor

Article Excerpt

BECKMAN COULTER INC. $64 (New York symbol BEC; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 69.9 million; Market cap: $4.5 billion; Price-to-sales ratio: 1.4; Dividend yield: 1.1%; WSSF Rating: Average) makes lab equipment that doctors and medical researchers use to detect substances in bodily fluids. Under Obamacare, Beckman and other medical-device makers will have to pay new fees, which they will attempt to pass on to their customers. Of course, expanded health care should lead to greater demand for Beckman’s tests. Right now, however, the market is focusing on more immediate matters. The stock fell 7% in mid-March due to problems with a test kit that determines whether a patient has suffered a heart attack. Beckman is working with the U.S. FDA to fix the problem. Meanwhile, it is advising clients to use other tests. This product generated $30 million in revenue for Beckman in 2009, or 1% of the total. But Beckman also had to recall a sodium-testing system recently. This…